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BACKGROUND AND PURPOSE
Reducing glucocorticoid exposure in the brain via intracellular inhibition of the cortisol-regenerating enzyme 11β-hydroxysteroid
dehydrogenase type 1 (11β-HSD1) has emerged as a therapeutic strategy to treat cognitive impairment in early Alzheimer’s
disease (AD). We sought to discover novel, brain-penetrant 11β-HSD1 inhibitors as potential medicines for the treatment of AD.
EXPERIMENTAL APPROACH
Medicinal chemistry optimization of a series of amido-thiophene analogues was performed to identify potent and selective
11β-HSD1 inhibitors with optimized oral pharmacokinetics able to access the brain. Single and multiple ascending dose studies
were conducted in healthy human subjects to determine the safety, pharmacokinetic and pharmacodynamic characteristics of
the candidate compound.
RESULTS
UE2343 was identified as a potent, orally bioavailable, brain-penetrant 11β-HSD1 inhibitor and selected for clinical studies. No
major safety issues occurred in human subjects. Plasma adrenocorticotropic hormone was elevated (a marker of systemic enzyme
inhibition) at doses of 10 mg and above, but plasma cortisol levels were unchanged. Following multiple doses of UE2343, plasma
levels were approximately dose proportional and the terminal t1/2 ranged from 10 to 14 h. The urinary
tetrahydrocortisols/tetrahydrocortisone ratio was reduced at doses of 10 mg and above, indicating maximal 11β-HSD1 inhibition
in the liver. Concentrations of UE2343 in the CSF were 33% of free plasma levels, and the peak concentration in CSF was ninefold
greater than the UE2343 IC50.
CONCLUSIONS AND IMPLICATIONS
UE2343 is safe, well tolerated and reaches the brain at concentrations predicted to inhibit 11β-HSD1. UE2343 is therefore a
suitable candidate to test the hypothesis that 11β-HSD1 inhibition in brain improves memory in patients with AD.
Abbreviations
ACTH, adrenocorticotropic hormone; AD, Alzheimer’s disease; Ae, amount excreted; Aβ, amyloid β; b.i.d, twice daily; BMI,
body mass index; CLR, renal clearance; Cmax, maximum plasma concentration; Cmin, minimum plasma concentration; CV,
coefficient of variation; CYP450, cytochrome P450; DHEA-s, dehydroepiandrosterone sulphate; HPA, hypothalamic–-
pituitary-adrenal; HSD, hydroxysteroid dehydrogenase; MPO, multiparameter optimization; q.d, once daily; TEAEs, treat-
ment-emergent adverse events; TH, tetrahydro; THE, tetrahydrocortisone; THF, tetrahydrocortisol; Tmax, time tomaximum
plasma concentration
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Introduction
Chronically elevated levels of the glucocorticoid stress hor-
mone cortisol are associated with a variety of conditions in-
cluding Cushing’s syndrome, which is characterized by the
metabolic complications of central obesity, dyslipidaemia,
hypertension and glucose dysregulation (Anagnostis et al.,
2009). In Cushing’s syndrome, neuropsychiatric problems
also occur, including cognitive impairment, which is related
to excess cortisol exposure in key areas of the brain responsi-
ble for memory (Starkman et al., 1999). Increased glucocorti-
coid exposure in the brain is linked to age-related cognitive
decline where cortisol levels align with reductions in hippo-
campal volumes and consequent memory impairment
(Lupien et al., 1998; MacLullich et al., 2005; Lupien et al.,
2009). More subtle alterations in glucocorticoid levels,
exemplified by higher morning cortisol levels, have also been
shown to be associated with impaired cognitive performance
(Reynolds et al., 2010).
In Alzheimer’s disease (AD), elevated plasma cortisol
levels are associated with accelerated disease progression,
while higher cortisol levels in CSF are associated with more
rapid clinical worsening and cognitive decline in mild cogni-
tive impairment of the AD type (Cernansky et al., 2006;
Kornhuber and Jessen, 2015; Popp et al., 2015). Individuals
with the APOE-ε4 allele, a key risk factor for AD, have higher
CSF cortisol (Peskind et al., 2001). Studies in rodents have
provided further evidence that excess glucocorticoids link to
disease progression with synthetic glucocorticoid treatment
leading to increased amyloid β (Aβ) formation, reduced Aβ
degradation and increased τ expression in the brain (Green
et al., 2006). Reducing glucocorticoid action may therefore
be beneficial in the treatment of AD.
Directly manipulating the hypothalamic–pituitary-
adrenal (HPA) axis in AD is not attractive, since a reduction
in circulating cortisol risks impairing the stress response.
However, tissue-specific modulation of intracellular cortisol
levels without concomitant reductions in plasma cortisol
can be achieved by inhibiting the cortisol-generating enzyme
11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) in rele-
vant brain areas including the hippocampus. Pharmacologi-
cal inhibition of 11β-HSD1 leads to reduction in Aβ plaques
in the brains of Tg2576-AD mice and to improvements in
memory (Sooy et al., 2015). In aged rodents, modulation of
11β-HSD1 by genetic knockdown or pharmacological inhibi-
tion improves memory (Yau et al., 2001; Sooy et al., 2010;
Mohler et al., 2011; Yau et al., 2014), while treatment of cogni-
tively impaired healthy elderly men and patients with type 2
diabetes, with the non-selective 11β-HSD1 inhibitor
carbenoxolone, has been shown to improve memory
(Sandeep et al., 2004). Lowering cortisol levels in the brain
via inhibition of 11β-HSD1 has thus emerged as a therapeutic
strategy for the treatment of cognitive impairment in early-
stage AD (Reynolds and Webster, 2015).
Here, we report the discovery of the brain-penetrant
11β-HSD1 inhibitor UE2343 and the results of Phase 1 clin-
ical studies to establish its safety, pharmacokinetics, distri-
bution to the brain and tissue-specific pharmacodynamics.
Methods
Chemical synthesis
The synthetic methods for the preparation of compounds 1
to 9 are reported in patent applications WO2011033255 and
WO2011135276 (Webster et al., 2011a,b).
11β-HSD1 inhibition
Inhibition of human 11β-HSD1 was determined in HEK293
cells stably transfected with a construct containing the full-
length gene coding for the human 11β-HSD1 enzyme accord-
ing to the protocol described by Sooy et al., 2010.
Microsomal stability
Microsomal stability was determined using pooled human,
rat or dog liver microsomes according to the method de-
scribed in WO2011135276 (Webster et al., 2011a).
Tables of Links
TARGETS
Voltage-gated ion channelsa Enzymesc
hERG (Kv11.1) channels 3α-reductase (AKR1C3)
Nuclear hormone receptorsb 5α-reductase
Glucocorticoid receptor (GR) 11β-HSD1
Mineralocorticoid receptor (MR) CYP1A2
CYP2C9
CYP2C19
CYP2D6
CYP3A4
LIGANDS
4-androstenedione
ACTH
Amyloid β
Cortisol
Cortisone
DHEA-s
Testosterone
These Tables list key protein targets and ligands in this article which are hyperlinked to corresponding entries in http://www.guidetopharmacology.org,
the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016), and are permanently archived in the Concise Guide to
PHARMACOLOGY 2015/16 (a,b,cAlexander et al., 2015a,b,c).
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Plasma protein binding
Plasma protein binding was determined using pooled
human plasma according to the method described in
WO2011135276 (Webster et al., 2011a).
hERG inhibition
Testing was performed by Essen Instruments, Hertfordshire,
UK. Compounds were tested for inhibition of the human
ether a go-go related gene (hERG) K+ channel in a Chinese
hamster lung cell line stably expressing the full length hERG
channel. Single cell ionic currents were measured in the
perforated patch clamp configuration at room temperature
using an IonWorks Quattro instrument. Eight-point
concentration–response curves were generated using three-
fold serial dilutions from themaximum final assay concentra-
tion. IC50 values were obtained from a four-parameter logistic
fit of the % inhibition data.
Aqueous solubility
Aqueous solubility was determined by suspending sufficient
compound in aqueous buffer (0.1 M potassium phosphate,
pH 7.4; 0.15 M potassium chloride) to give a maximum possi-
ble final concentration of 1 mg·mL1 of the compound at
room temperature. The concentration was quantified by
HPLC with reference to a standard calibration curve. The sol-
ubility was calculated using the peak areas determined by in-
tegration of the peak found at the same retention time as the
principal peak in the standard injection.
Cytochrome P450 inhibition
Testing was performed by Cyprotex Discovery Limited,
Cheshire, UK. Six test compound concentrations (0.4, 1, 4,
10, 40 and 100 μM; final DMSO concentration 0.25%, final
microsome concentration 0.25 mg·mL1) were either pre-
incubated for 30 min in the absence and presence of NADPH
or underwent a 0 min pre-incubation with human liver mi-
crosomes. At the end of the pre-incubation period, the probe
substrate for each cytochrome P450 (CYP450) isoform
(30 μM) and NADPH (1 mM) were then added (final DMSO
concentration 0.3%), and the samples were incubated for
5min at 37°C. Probe substrates were as follows: 1A2 – phenac-
etin, 2C9 – diclofenac, 2C19 – mephenytoin, 2D6 – dextro-
methorphan, 3A4 – midazolam and testosterone. Samples
were subjected to LC–MS/MS analysis to determine metabo-
lite concentrations. A decrease in the formation of the metab-
olite compared with vehicle control was used to calculate an
IC50 value (test compound concentration which produces
50% inhibition) for each experimental condition.
Pharmacokinetics in rat
Pharmacokinetic studies were carried out at Quotient
Bioresearch, UK. For both i.v. and p.o. administration, com-
pounds were prepared in 0.9% saline containing 2% DMSO
(v.v-1) and 38% PEG400 (v.v-1). Solutions were passed through
0.22 μm filters prior to administration. Animals were given ad
libitum access to food and water throughout the study.
For i.v. administration three male Sprague Dawley rats
each received 1 mg·kg1 of compound by tail vein injection
(dose volume 5 mL·kg1). Serial blood samples were taken
from a lateral tail vein 5, 15, 30 min, 1, 2, 4, 6 and 8 h post
i.v. administration, and stored in individual EDTA containers.
Blood samples were flash frozen in liquid nitrogen and stored
at 20°C prior to analysis.
For p.o. administration, five male Sprague Dawley rats
were dosed with compound at 5 mg·kg1 (dose volume
10 mL·kg1). Serial blood samples were taken from a lat-
eral tail vein 15, 30 min, 1, 2, 4, 6 and 8 h post p.o. adminis-
tration, and stored in individual EDTA containers. Blood
samples were flash frozen in liquid nitrogen and stored at
20°C prior to analysis.
Blood samples were thawed at ambient temperature and
vortex mixed thoroughly. A representative aliquot of each
blood sample was diluted 1:1 v.v-1 with HPLC grade water
prior to protein precipitation with acetonitrile containing di-
azepam internal standard (blood/water: acetonitrile ratio was
1:4 v v-1). Following vortex mixing and centrifugation (4°C,
15 min, 17 000 x g) a 100 μL aliquot of supernatant was di-
luted by addition of 50 μL HPLC grade water in a well of a
96-well midi-eppendorf plate. The plate was sealed and
shaken on a plate shaker to ensure sample homogeneity. Sam-
ples were assayed against a series of matrix matched calibra-
tion curve standards by LC–MS/MS using a Sciex 3000 mass
spectrometer. Pharmacokinetic parameters were derived by
non-compartmental analysis using WinNonLin pharmacoki-
netic software.
Animals were group-housed, provided free access to food
and water and maintained in accordance with UK Home Of-
fice regulations and according to established procedures. Fol-
lowing the final blood sample animals were killed via a
Schedule 1 method.
Pharmacokinetics in dog
Pharmacokinetic studies were carried out at Charles River, UK.
For both i.v. and p.o. administration, compounds were pre-
pared in 0.9% saline containing 2% DMSO (v.v-1) and 38%
PEG400 (v.v-1). Solutions were passed through 0.22 μm filters
prior to administration. Three Beagle dogs each received a sin-
gle i.v. injection of compound 4 at a dose level of 1 mg·kg1.
Following a washout period of 1 week, each animal received
a single p.o. dose of compound 4 at a dose level of 5 mg·kg1.
After a washout period of 6 weeks, the same three dogs
each received a single i.v. injection of compound 7 at a dose
level of 1 mg·kg1. Following a washout period of 1 week,
each animal received a single p.o. dose of compound 7 at a
dose level of 5 mg·kg1.
Plasma samples were obtained up to 24 h post dose ad-
ministration, and the concentration of each test item in
plasma was determined using LC–MS/MS. Pharmacokinetic
parameters were derived by non-compartmental analysis
using WinNonLin pharmacokinetic software.
During pre-trial and on-study periods, animals were
group-housed and maintained according to established pro-
cedures as detailed in appropriate standard operating proce-
dures (SOPs) and in accordance with UK Home Office
regulations. Except for a period of fasting, pre-dose to approx-
imately 4 h post-dose animals were fed a daily allowance of
400 g of standard laboratory diet and mains quality tap water
was available ad libitum throughout the study. Following
completion of the study animals were returned to the colony.
The animal work was conducted under UK Home Office Pro-
ject Licence no. PPL 60/4186.
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Tissue exposure measurements in rats
The circulating plasma levels and tissue distribution of com-
pounds were determined according to the method described
in WO2011135276 (Webster et al., 2011a). Animals were
group-housed, had free access to food and water and were
maintained in accordance with UK Home Office regulations.
The animal work was conducted under UK Home Office Pro-
ject Licence no. PPL 60/3915.
Compounds were prepared in 0.9% saline containing
2% DMSO (v.v-1) and 38% PEG400 (v.v-1) and administered
to male Sprague Dawley rats by oral gavage such that the
final concentration of compound was 10 mg·kg1. Rats
(n = 3 per time point) were killed by decapitation at 1, 4
and 6 h post dosing, and trunk blood and tissues (liver,
adipose and brain) were excised. Blood samples at 0.5 and
2 h post dosing were taken by a tail nick from the 4 and
6 h rats respectively.
Compounds were triple extracted from plasma (prepared
from blood by a high speed centrifugation step) and spiked
with 1 μg of a standard compound using ethyl acetate. Ex-
tracts were dried under nitrogen and re-suspended in 60%
methanol/40% ammonium acetate (5 mM).
A known weight of tissue was homogenized in 3 volumes
of Krebs buffer. The compoundwas triple extracted with ethyl
acetate from the supernatant of a low speed spin spiked with
1 mg of a standard compound. Extracts were dried under ni-
trogen and re-suspended in 60% methanol/40% ammonium
acetate (5 mM).
Samples from plasma and tissue were analysed by TSQ
Quantum Discovery Tandem Mass Spectrometer and Sur-
veyor Liquid Chromatogram (Thermo, Hemel-Hempstead,
UK). Then 10 μL of each sample was injected in a mobile
phase consisting of 60% methanol/40% ammonium acetate
(5 mM) at a flow rate of 0.5 mL·min1. The column used
was a BDS hypersil C18, 50 × 2.1mmwith a 5 μmparticle size.
Each compound was tuned with a spray voltage of 3000 V
and a capillary temperature of 300°C, and values for tube
lens, CID and product ions were determined. The peak area
for each compound and for the internal standard was deter-
mined, and the concentration of compound . g-1 of tissue or
mL-1 of plasma was calculated by comparison of the peak area
ratio to a standard curve.
Compliance with requirements for studies using
animals
Studies using animals were carried out in accordance with UK
Home Office regulations under appropriate project licences.
Pharmacokinetic and tissue exposure measurements were
carried out using standard study designs, and the numbers
of animals used per study were in line with those required
to support regulatory submissions to the UK Medicines and
Healthcare products Regulatory Agency. Animal studies are
reported in compliance with the ARRIVE guidelines (Kil-
kenny et al., 2010; McGrath & Lilley, 2015).
Clinical study design and subject
characteristics
Single ascending dose study. A double-blind, randomized,
placebo-controlled single ascending dose study was carried
out at Simbec Research Ltd, Merthyr Tydfil, UK. Each cohort
consisted of six healthy male subjects and two females of
non-child bearing potential. Two male ‘dose leader’ subjects
(1 active : 1 placebo) were dosed first in each cohort. The
remainder of the cohort (5 active : 1 placebo) were dosed
24 h later. Dose cohorts were 2, 5, 10, 18, 25 and 35 mg.
Safety, pharmacokinetic and pharmacodynamic assessments
were made at pre-determined time-points during each part
of the study. Dose escalation was dependent upon
satisfactory review of the blinded safety (up to Day 6) and
pharmacokinetic (up to 24 h post-dose) data from the
preceding cohort.
Multiple ascending dose study. A double-blind, randomized,
placebo-controlled multiple ascending dose study was
carried out at Linear Clinical Research Ltd, Nedlands,
Australia. Each cohort consisted of eight healthy male
subjects. Each subject received UE2343 or placebo twice
daily (b.i.d ) (12 hourly) in the fed state for 9 days (Day 1 to
Day 9) and once on the morning of Day 10 (19 doses in
total). Dose cohorts were 10, 20 and 35 mg. Dose escalation
and selection was dependent upon satisfactory review of the
blinded safety (up to Day 17 ± 2) and plasma
pharmacokinetics (up to Day 12) data from the preceding
cohort. Safety, pharmacokinetic and pharmacodynamic
assessments were made at pre-determined time-points
during each part of the study.
CSF study. A non-randomized, open label, multiple dose
phase I study to determine the pharmacokinetic parameters
of UE2343 in CSF was carried out at Linear Clinical Research
Ltd, Nedlands, Australia. Four healthy male subjects each
received 35 mg UE2343 b.i.d (12 hourly) fed (30 min after
the start of a standard meal) for 3 days (Day 1 to Day 3) and
once on the morning of Day 4 (seven doses in total). Plasma
pharmacokinetic samples were taken from each subject on
Day 1 and Day 4. A single CSF sample was taken from each
subject at 5 h post-final dose on Day 4, corresponding to the
plasma Tmax (time to maximum plasma concentration).
Approval for each clinical study was obtained following
review of protocols by local research ethics committees.
Analytical methods
Laboratory evaluation of clinical safety parameters was car-
ried out using standard validated methods. Measurement of
plasma pharmacodynamic markers [adrenocorticotropic hor-
mone (ACTH), cortisol, 4-androstenedione, testosterone and
dehydroepiandrosterone sulphate (DHEA-s)] was carried out
using commercially available kits. Each method was fully val-
idated prior to analysis. Urinary steroid metabolites were
measured according to established methods (Boonen et al.,
2013). UE2343 levels in plasma, urine and CSF was deter-
mined by LC–MS/MS using fully validated methods.
Statistical analysis
The data and statistical analysis comply with the recom-
mendations on experimental design and analysis in phar-
macology (Curtis et al., 2015). Levels of probability,
P < 0.05 were deemed to constitute the threshold for statis-
tical significance. Pharmacokinetic parameters, except Tmax
(time of maximum observed drug concentration), are given
as mean ± coefficient of variation (CV%). Tmax is given as
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median ± range. For each of the pharmacodynamic parame-
ters [ACTH, cortisol, adrenal androgens, tetrahydrocortisols
(THFs)/tetrahydrocortisone (THE) ratio], the maximum %
change from baseline for each subject was subjected to
ANOVA. For selected data, an additional covariate factor
for the baseline was also included in the ANOVA/analysis
of covariance (ANCOVA) model. Associated P-values <0.05
for each comparison have been presented.
The ACTH levels for each individual given a single dose of
UE2343 on Day 1 (0 and 23 h post-dose) were also subjected
to a fixed effects ANOVA, with a fixed effect for dose level.
The associated P-values <0.05 between 0 and 23 h post-dose
have been presented.
Unless stated otherwise, data has been plotted as
mean ± SEM.
Results
Selection of UE2343 for clinical studies
A series of 3,3-disubstituted-(8-aza-bicyclo[3.2.1]oct-8-yl)-[5-
(1H-pyrazol-4-yl)-thiophen-3-yl]-methanones were discov-
ered that displayed potent and selective inhibition of human
11β-HSD1 as exemplified by compound 1 (Figure 1) (Webster
et al., 2011a). Final lead optimization focused on improving
the physicochemical and pharmacokinetic characteristics of
the lead series by examining heterocyclic alternatives to the
3-phenyl group of compound 1 and by replacement of the
3-hydroxyl group with fluorine or nitrile (Figure 1). Physico-
chemical parameters were aligned with those required for
brain penetration since potential candidate compounds
were required to enter the brain. CNS multiparameter opti-
mization (MPO) calculations were also performed leading
to the generation of a subset of compounds with CNS
MPO scores ≥5 that were predicted to cross the
blood–brain barrier (Table 1) (Wager et al., 2010). All com-
pounds displayed good levels of potency in cellular assays
of 11β-HSD1 (IC50 < 50 nM) and selectivity at the isozyme
11β-HSD2 (IC50 > 10 μM, data not shown). Hydroxyl, fluo-
rine and nitrile groups were well tolerated in combination
with a variety of heterocycles. Single 3-exo isomers were ob-
tained for hydroxyl and nitrile analogues, but synthesis of
fluorinated analogues (compounds 6 and 7) led to the prep-
aration of both 3-exo and 3-endo isomers (Webster et al.,
2011b). The 3-exo isomer (compound 7) displayed greater
potency towards 11β-HSD1 than the corresponding 3-endo
isomer (compound 6) and possessed improved pharmacoki-
netic properties compared with the 3-endo isomer, includ-
ing a twofold greater free fraction in plasma.
Plasma and brain partitioning was determined by
conducting tissue exposure studies in rats. The greatest
brain : plasma ratio was obtained for the pyridine analogues
3, 6 and 7 (Table 1). However, only the 3-fluoro-3-pyridine
analogue 7 displayed sufficient oral bioavailability for fur-
ther consideration. Moderate CNS exposure was obtained
for the 3-hydroxy-3-pyrimidine analogue 4, which displayed
comparable plasma levels to compound 7. When rat plasma
protein binding was taken into account (Table 2) the
brain : plasma free ratios were 2.45 for compound 7 and
0.43 for compound 4, indicating that a greater proportion
of compound 7 was also able to enter the CNS.
Further pharmacokinetic comparison of compounds 4
and 7 was performed in dogs, which demonstrated that both
compounds exhibited high bioavailability and moderate
half-lives (Table 2). Compound 4 was cleared more slowly
than compound 7 in line with its greater in vitro stability in
dog liver microsomes (Table 2). Strikingly compound 4 gave
greater than threefold higher oral exposure than compound
7 and displayed >100% bioavailability. The reasons for a bio-
availability value of >100% are unknown and there was no
evidence of enterohepatic recirculation.
Although compound 7 demonstrated higher levels in rat
brain than compound 4, profiling of both compounds
in vitro demonstrated that compound 4 possessed a more
attractive profile for further development in humans than
compound 7, including substantially greater stability in
human liver microsomes, higher free fraction in human
plasma and higher aqueous solubility (Table 2). Crucially,
compound 4 displayed only marginal inhibition of the
hERG channel up to a concentration of 30 μM, whereas
Figure 1
Lead structure and properties. Pharmacokinetics in rats was conducted by i.v. (n = 3 rats) and p.o. administration (n = 5 rats). The number of in-
dividual experiments [n] for measurement of in vitro human 11β-HSD1 inhibition, plasma protein binding and aqueous solubility are shown. Data
are reported as mean ± SD.
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compound 7 was a moderate hERG inhibitor (IC50 = 3.1 μM,
Table 2). Subsequent in vitro profiling of compound 4
revealed a clean off-target profile in a diversity screen of 29
enzymes and 72 receptors, including the glucocorticoid
and mineralocorticoid receptors (data not shown). For com-
pound 4, no significant CYP450 inhibition was observed at
isoforms 1A2, 2D6, 2C9 or 3A4 ((IC50 > 50 μM). However,
moderate inhibition of isoform 2C19 (IC50 = 1.7 μM) was
observed. No time-dependent inhibition was observed at
any of the CYP450 enzymes tested. Compound 4 was thus
chosen for further development in humans and designated
with the code UE2343.
Subject demographics and safety
A single ascending dose study was conducted in 36 healthy
male subjects (35 Caucasians and 1 Afro-Caribbean) and 12
healthy Caucasian females of non-child bearing potential.
For males, the mean age was 34.1 ± 9.7 years and the mean
body mass index (BMI) was 26.0 ± 2.4 kg·m2. For females,
the mean age was 49.3 ± 9.1 years and the mean BMI
was 25.1 ± 2.1 kg·m2. Each cohort consisted of six males
and two females. The incidence of treatment-emergent
adverse events (TEAEs) was considered to be low (number
of subjects with ≥1 TEAEs: placebo = 6, UE2343 = 9), and
none was associated with any clinically significant changes
in vital signs, ECG, biochemistry, haematology or urinaly-
sis data.
A multiple ascending dose study was conducted in 24
healthy male subjects (4 Caucasians and 20 Asians) with a
mean age of 26.7 ± 5.4 years and a mean BMI of 23.9 ± 1.9-
kg·m2. No serious TEAEs or TEAEs that led to subject with-
drawal from the study were reported, and all TEAEs were
mild or moderate in intensity. The most common TEAE was
headache reported in 7/24 subjects; diarrhoea was reported
in 2/24 subjects, and thrombophlebitis was reported in 3/24
subjects.
A study to determine the amount of UE2343 in CSF was
conducted in four healthy Asian male subjects with mean
age of 29 ± 11 years and mean BMI of 24.6 ± 1.4 kg·m2. All
TEAEs were mild to moderate in intensity. Vital signs
remained stable during the study, and no out of the range
values were recorded for any of the subjects during the
study. Increased alanine aminotransferase was reported in
a single subject.
Table 1
Potency, plasma and brain levels of compounds 1–9
ID X R IC50 (nM) [n] CNS MPO score
Plasma Cmax
(ng·mL1)
Brain Cmax
(ng·mL1)
Brain : plasma
ratio
1 OH 22 ± 2 [2] 5.0 419 ± 28 29 ± 10 0.07
2 OH 26 ± 8 [3] 5.4 1270 ± 330 31 ± 12 0.02
3 OH 12 ± 0 [1] 5.0 115 ± 48 36 ± 12 0.31
4 OH 24 ± 15 [31] 5.2 1539 ± 657 173 ± 80 0.11
5 OH 37 ± 3 [2] 5.2 589 ± 161 19 ± 17 0.03
6 F 22 ± 10 [4] 5.4 399 ± 99 108 ± 54 0.27
7 F 7 ± 4 [5] 5.4 1526 ± 212 374 ± 184 0.24
8 CN 15 ± 0 [1] 5.6 291 ± 74 9 ± 3 0.03
9 CN 13 ± 3 [3] 5.3 230 ± 33 15 ± 1 0.07
Plasma and brain levels were determined as described in the section using n = 3 rats per time point. The number of individual experiments [n] for
measurement of in vitro human 11β-HSD1 inhibition are shown. Data are reported as mean ± SD.
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Pharmacokinetics
In the single ascending dose study UE2343 reached a maxi-
mum plasma concentration (Cmax) within 3.5–4 h following
administration of 10, 18, 25 and 35 mg of UE2343 (Figure 2).
Plasma levels of UE2343 at doses of 2 and 5 mg were below
the level of quantification, and data are not reported. Plasma
UE2343 levels increased with increasing dose and overall ex-
posure, as measured by Cmax and AUC (AUC0-t and AUC0-∞),
increased in a greater than proportional manner with increas-
ing dose (Table 3). The greatest increase in exposure was ob-
served between 10 and 18 mg UE2343, with an approximate
fourfold increase between each of these two doses. UE2343
concentrations appeared to start to plateau between the 25
and 35 mg dose levels. The t1/2 ranged from 10.5 to 18.7 h
and the oral clearance from 7.3 to 8.8 l·h1. Both parameters
were dose-independent following single doses. Urinary excre-
tion of UE2343 accounted for ≤1.8% of the respective doses,
with a renal clearance (CLR) of <0.13 l·h
1. The amount of
UE2343 excreted in urine over the 120 h sampling period
(amount excreted [Ae](0–120h)), increased with dose in a
greater than proportional manner across the 10 mg to the
35 mg dose levels, with the greatest increase observed
between the 10 and 18 mg dose levels.
In the multiple ascending dose study, the pharmacoki-
netic parameters of UE2343 at dose levels of 10, 20 and
35 mg administered every 12 h were determined on Days 1
and 10. Plasma UE2343 levels as measured by Cmax, and
AUC over 12 h (AUC0–12) were approximately dose propor-
tional on Day 10 (Table 4). However, these parameters in-
creased more rapidly than proportionally to dose level on
Day 1. Steady state was achieved by Day 5 and the terminal
Table 2
Comparative in vitro and in vivo properties of compounds 4 and 7
Compound 4 7
Human 11β-HSD1 IC50 in HEK293 cells (nM) [n] 24 ± 15 [31] 7 ± 4 [5]
Liver microsomal stability(% parent at 30 min) [n] Human Human
99 ± 1 [3] 51 ± 3 [3]
Dog Dog
92 ± 5 [3] 74 ± 1 [3]
Rat Rat
74 ± 1 [3] 45 ± 5 [3]
Pharmacokinetics in dog
Oral Cmax (ng·mL
1) 4590 ± 546 3100 ± 908
Cl (mL·min1·kg1) 4.68 ± 1.12 8.68 ± 2.03
t1/2 (h) 2.79 ± 0.84 3.21 ± 1.61
Oral AUC(0➔∞) (ng.h·mL
1) 31 730 ± 3746 9208 ± 2005
% F 170 ± 40 90 ± 40
Plasma protein binding(% unbound) [n] Human Human
30 ± 2 [2] 11 ± 2 [2]
Dog Dog
44 ± 0 [1] 11 ± 0 [1]
Rat Rat
26 ± 0 [2] 10 ± 1 [2]
Human hERG IC50 (μM) [n] >30 ± 0 [2] 3.1 ± 0.6 [2]
Aqueous solubility at pH 7.4 (mg·mL1) [n] 0.200 ± 0 [1] 0.006 ± 0 [1]
Pharmacokinetics in dog was conducted by i.v. and p.o. administration (n = 3 dogs per route). The number of individual experiments [n] for mea-
surement of in vitro human 11β-HSD1 inhibition, liver microsomal stability, plasma protein binding, hERG inhibition and aqueous solubility are shown.
Date are reported as mean ± SD.
Figure 2
UE2343 concentrations following a single oral dose of UE2343. Six
healthy male and two healthy female subjects per dose level.
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t1/2 ranged from 10 to 14 h. The median time to peak concen-
tration following each dose ranged from 4 to 6 h. There was
considerable accumulation with 12 hourly dosing, with in-
crease in AUC0–12 fromfirst dose to steady state of greater than
fourfold at the highest dose level. The Ae in urine was low,
with the fraction excreted in the dosing interval approxi-
mately 4% at steady state.
The concentrations of UE2343 in plasma and CSF were
determined during administration of 35 mg b.i.d for 4 days.
Mean Cmax on Days 1 and 4 was reached at 5 h post-dose
(Table 5). The extent of accumulation of UE2343 in plasma
after repeated daily dosing on Day 4 was 3.3-fold, consistent
with an elimination t1/2 in the order of 1 day. Between-subject
variability in the extent of systemic exposure to UE2343 was
high with geometric CVs for Cmax and AUC0–12 of 59 to
81%. A single CSF sample was taken from each subject at
5 h post-dose on Day 4. The mean concentration of
UE2343 in the CSF was 69.8 ng·mL1, ranging from 41.2
to 99.9 ng·mL1 and 7.46 to 11.9% of simultaneous total
plasma levels (Table 5).
HPA axis hormones and steroids
Following single dose administration of UE2343, there was
no effect on serum cortisol, 4-androstenedione or testoster-
one levels at any of the doses tested (Supporting Information
Fig. S1A–C). DHEA-s was higher following UE2343 adminis-
tration when compared to placebo with statistically signifi-
cant increases observed at 2 (P < 0.05, data not shown), 5
(P < 0.05, data not shown) and 35 mg (P < 0.05) UE2343.
The increases in DHEA-s were of similar magnitude indicat-
ing that there was no apparent dose–response relationship
(Supporting Information Fig. S1D). There was a dose-
dependent increase in plasma ACTH across the 18–35 mg
dose range (Figure 3A). When compared with placebo, a sta-
tistically significant increase was observed for the 35 mg dose
level (P < 0.05). The time to maximum % change was shown
to occur at a median of 23–27 h post-dose at all dose levels ex-
cept 2 mg UE2343, and values had returned to baseline by ap-
proximately 47 h post-dose. Within-group comparisons also
revealed a statistically significant increase in ACTH 23 h
post-dose when compared with pre-dose levels following 10
Table 3
Pharmacokinetic parameters following a single oral dose of UE2343 in humans
Pharmacokinetic
parameter
UE2343
10 mg Mean
(CV%)
18 mg Mean
(CV%)
25 mg Mean
(CV%)
35 mg Mean
(CV%)
Cmax (ng·mL
1) 40.4 (62%) 136 (46%) 278 (30%) 329 (37%)
Tmax (h)
1 3.5 (3–6) 4.0 (3–4) 4.0 (3–6) 4.0 (4–6)
t1/2 (h) 18.7 (59%) 13.6 (61%) 10.5 (35%) 11.4 (24%)
AUC0-t (ng
.h·mL1) 550 (90%) 2291 (87%) 3486 (39%) 4016 (30%)
AUC0-∞ (ng
.h·mL1) 856 (70%) 2581 (84%) 3825 (35%) 4261 (29%)
Oral clearance (L·h1) 18.5 (75%) 14.5 (90%) 7.32 (38%) 8.78 (28%)
Ae(0–120h) (μg) 52.5 (85%) 300 (66%) 438 (37%) 501 (15%)
Ae(0–120h) (%) 0.53 (85%) 1.67 (66%) 1.75 (37%) 1.43 (15%)
CLR (L·h
1) 0.07 (86%) 0.16 (50%) 0.13 (46%) 0.12 (16%)
Single ascending dose studies were conducted in six healthy male and two healthy female subjects per dose level.
1Median ± range
Table 4
Pharmacokinetic parameters following multiple oral doses of UE2343 in humans
Pharmacokinetic
parameter
Day 1 Day 10
10 mg UE2343
Mean
(CV%)
20 mg UE2343
Mean
(CV%)
35 mg UE2343
Mean
(CV%)
10 mg UE2343
Mean
(CV%)
20 mg UE2343
Mean
(CV%)
35 mg UE2343
Mean
(CV%)
Cmax (ng·mL
1) 29.1 (61%) 89.2 (71%) 268 (34%) 207 (58%) 365 (29%) 892 (30%)
Tmax (h)
1 6.0 (4–8) 4.0 (3–10) 4.0 (3–6) 4.0 (3–6) 3.0 (2–6) 4.0 (3–6)
t1/2 (h) nd nd nd 13.8 (21%) 11.2 (25%) 9.99 (14%)
AUC0–12h(ng
.h·mL1) 207 (79%) 623 (69%) 1843 (33%) 1917 (66%) 3175 (30%) 7909 (36%)
Oral clearance (L·h1) nd nd nd 7.24 (60%) 6.85 (33%) 5.02 (43%)
Ae(0–12h) (μg) 34.6 (50%) 107 (92%) 362 (46%) 408 (46%) 644 (38%) 1345 (29%)
Ae(0–12h) (%) 0.35 (50%) 0.54 (92%) 1.03 (46%) 4.08 (46%) 3.22 (38%) 3.84 (29%)
Multiple ascending dose studies were conducted in eight healthy male subjects per dose level.
1Median ± range
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(P < 0.05), 25 (P < 0.05) and 35 mg (P < 0.05) UE2343, indi-
cating stimulation of the anterior pituitary component of
the HPA axis (Figure 3B).
No dose-dependent relationship was observed for
changes in cortisol, testosterone, 4-androstenedione or
DHEA-s following multiple doses of UE2343 (Supporting
Information Fig. S2A–E). For cortisol, the only statistically
significant difference observed was between the 20 mg
UE2343 group and placebo (P < 0.05) (Supporting Informa-
tion Fig. S2A–B). When compared with placebo, statistically
significant increases in 4-androstenedione from baseline
were observed for doses of 10 (P < 0.05) and 20 mg
(P < 0.05) (Supporting Information Fig. S2C). DHEA-s was
increased from baseline, with statistically significant differ-
ences observed between the 10 mg UE2343 group and
placebo (P < 0.05) as well as the 35 mg UE2343 group
and placebo (P < 0.05); there was a trend towards an
increase at 20 mg (P = 0.0505) (Supporting Information
Fig. S2E). The mean maximum percentage change in ACTH
(from baseline) was 222, 195 and 230% for the 10, 20 and
35 mg UE2343 doses, respectively, but these differences
were not statistically significant when compared with
placebo across the 13 day sampling period (Supporting
Information Fig. S3).
Pharmacodynamic inhibition of 11β-HSD1 in
the liver
11β-HSD1 is predominantly located in the liver and adipose
tissue. Cortisol (F) and cortisone (E) are cleared from the liver
via the enzymes 5α-reductase and 3α-HSD to generate
tetrahydro (TH) metabolites that are eliminated in the urine.
Measurement of urinary TH metabolite ratios thus provides a
surrogate measure of 11β-HSD1 inhibition in the liver (Best
and Walker, 1997). Following a single dose of UE2343, there
was a statistically significant reduction in the urinary
THFs/THE ratio between 0 and 4 h at doses of 18, 25 and
35mg, equating to a reduction of 58, 55 and 50% respectively
(Figure 4A). At 4–8 h, statistically significant reductions in the
THFs/THE ratio of 79, 86, 83 and 83%were observed for doses
of 10, 18, 25 and 35 mg respectively.
During the multiple ascending dose study statistically
significant differences in the THFs/THE ratio were observed
between placebo and all UE2343 treatment groups: 10
(P < 0.05), 20 (P < 0.05) and 35 mg (P < 0.05). Maximal
reduction (84–89% reduction) in the THFs/THE ratio was
achieved from 12 to 24 h on Day 1 across all dose levels
and was maintained throughout the dosing period
(Figure 4B).
Estimation of 11β-HSD1 inhibition in brain
The presence of UE2343 in the CSF samples taken from the
human subjects confirmed that the compound crosses the
blood brain barrier. UE2343 is 70% bound to plasma proteins;
therefore, at plasma Cmax on Day 4 (101 h), the mean UE2343
CSF levels were 33% of the free plasma levels (range: 25–40%)
and 10% of the total plasma levels (range: 7–12%) (Figure 5).
It was assumed that these ratios were maintained across all
dose levels and time points to calculate the likely concentra-
tions of UE2343 in the CSF at each of the dose levels used in
the multiple ascending dose study. From these calculations,
it was estimated that the mean CSF nadir at steady state
[minimum plasma concentration (Cmin)] was 13, 22 and
50 ng·mL1 at 10, 20 and 35 mg b.i.d. respectively. Maxi-
mal CSF concentrations were estimated to be 20, 34 and
81 ng·mL1 at 10, 20 and 35 mg b.i.d, suggesting that
steady state brain levels exceeded the IC50 value for
UE2343 (9 ng·mL1) across the dosing range.
Table 5
Pharmacokinetic parameters in plasma and CSF following 35 mg b.i.
d for 4 days
Pharmacokinetic
parameter
35 mg UE2343
Day 1 Mean
(CV%)
Day 4 Mean
(CV%)
CCSF, 5h (ng·mL
1) nd 69.8 (44%)
Cmax (ng·mL
1) 235 (60%) 708 (59%)
Tmax (h)
1 5.1 (4–6) 5.1 (3–5)
t1/2 (h) 6.24 (82%) 8.97 (39%)
AUC0–12h (ng.h mL
1) 1710 (66%) 5670 (81%)
The study was conducted in four healthy subjects.
1Median ± range
A
B
Figure 3
Plasma ACTH following a single oral dose of UE2343. Six healthy
male and two healthy female subjects per dose level. (A) ACTH levels
up to 125 h post-dose. (B) ACTH at 23 h post-dose; ANOVA
*P < 0.05.
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Discussion
A series of novel 11β-HSD1 inhibitors were evaluated in vitro
and in vivo with the objective of identifying a candidate
molecule with the correct blend of characteristics for chronic
oral administration in patients with AD. Physicochemical
parameters for lead compounds were aligned with those re-
quired for CNS penetration. In line with CNS MPO scores,
all compounds tested in vivo were able to access the CNS to
varying degrees, with compound 8 displaying the greatest
brain penetration. Notably, this compound contained a fluo-
rine in place of a hydroxyl. Although compound 7 possessed
higher in vitro potency towards 11β-HSD1 and a higher
brain : plasma free fraction in rats, its other properties were
suboptimal compared with compound 4 (UE2343), which
displayed a superior preclinical profile for further develop-
ment, including lower in vitro clearance in human liver micro-
somes, lower human plasma protein binding, a greater safety
margin at the human hERG channel and higher aqueous sol-
ubility. UE2343 was thus selected as a development candidate
for preclinical safety assessment followed by clinical evalua-
tion in humans.
Clinical evaluation of UE2343 in single and multiple as-
cending dose studies demonstrated that doses of 2 to 35 mg
UE2343 once daily (q.d) and 10 to 35 mg b.i.d were safe and
well tolerated in human subjects. As expected, the normal di-
urnal variation in plasma cortisol and overall cortisol concen-
trations were not altered by the administration of UE2343,
with the exception of a small dose-independent increase at
20 mg b.i.d. Regimens of 10 to 35 mg b.i.d were associated
with more pronounced changes in adrenal hormone produc-
tion linked to perturbation of the HPA axis, likely to be a
consequence of preventing peripheral regeneration of
cortisol and enhancing cortisol clearance. Following single
dose administration, statistically significant changes were
noted in the ACTH-dependent adrenal androgen DHEA-s
in plasma, but no changes in the other plasma, androgens
4-androstenedione or testosterone were observed. Curiously,
at doses of 2 and 5 mg, when the level of UE2343 in plasma
was below the level of quantification, statistically significant
changes in the concentration of plasma DHEA-s compared
with placebo were observed, which may indicate some mod-
ulation of the HPA axis associated with 11β-HSD1 inhibition
in the periphery at low doses of UE2343. The increase in
DHEA-s was accompanied by a profound increase in ACTH
at doses of 10, 25 and 35mg q.d. indicating substantial reduc-
tion of 11β-HSD1-mediated cortisol regeneration in tissues.
Compensatory up-regulation of the HPA axis in response
to 11β-HSD1 inhibition was also noted following multiple
doses of 10, 20 and 35 mg UE2343. Both 4-androstenedione
and DHEA-s were elevated, with effects persisting up to 3 days
after the termination of dosing (Supporting Information
Fig. S1C,E). Increases in ACTH secretion were also elevated
compared with placebo, although the changes did not
reach significance and no dose-dependence was noted.
The compensatory changes in ACTH secretion in response
to UE2343 administration were consistent with those ob-
served in studies of other 11β-HSD1 inhibitors, where simi-
lar increases in the adrenal androgens 4-androstenedione
and DHEA-s have also been noted (Rosenstock et al., 2010;
Feig et al., 2011; Shah et al., 2011; Lui et al., 2013; Freude
et al., 2016).
Extra-adrenal tissue generation of cortisol from cortisone
by 11β-HSD1 augments the circulating pool of cortisol, which
in turn affects the net metabolic clearance of cortisol from the
A
B
Figure 4
Urinary THFs/THE ratios. (A) Effects on Day 1 following a single dose
of UE2343; ANOVA *P < 0.05. Six healthy male and two healthy fe-
male subjects per dose level. (B) Effects up to Day 12 following mul-
tiple doses of UE2343; ANOVA, 10 (P < 0.05), 20 (P < 0.05) and
35 mg (P < 0.05). Eight healthy male subjects per dose level.
Figure 5
UE2343 levels in plasma and CSF following 4 days of administration
of 35 mg b.i.d in four healthy male subjects.
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liver. Sampling of pooled urine over 4 h periods allowed de-
tailed analysis of the THFs/THE ratio to determine 11β-HSD1
inhibition in liver. Maximal inhibition (83–89% reduction
in THFs/THE ratio) was achieved between 4 and 8 h following
single and multiple dosing of UE2343. Substantial inhibition
persisted for up to 48 h following withdrawal of UE2343 sug-
gesting long-lived enzyme inhibition. The results compare
favourably with those reported for other 11β-HSD1 inhibitors
tested in humans; ABT-384 was shown to decrease the
THFs/THE ratio by 87–97%, BI 135585 by 65–75% and
RO-5093151 by 86–92% (Lui et al., 2013; Heise et al.,
2014; Freude et al., 2016).
UE2343 was detected in plasma at doses of 10 mg and
above. Following a single dose of UE2343, the exposure
increased in a greater than proportional manner between 10
and 18 mg, but the increase in UE2343 concentration be-
tween 25 and 35 mg was sub-proportional suggesting that
saturation of an absorption or distribution pathway may oc-
cur at higher doses. This effect was not noted following repeat
dosing where plasma UE2343 levels were approximately dose
proportional on Day 10. Renal clearance (CLR) was low fol-
lowing single or multiple dosing of UE2343, with a small in-
crease in % Ae at day 10 to approximately 4%. The plasma
Tmax following single and multiple dosing was moderately
long (3–6 h). This compares with a Tmax = 1 h in dog and, in
humans, may suggest slow dissolution of drug in the stomach
or slow absorption across membranes; however, each of these
phenomena would be inconsistent with the physicochemical
properties of UE2343.
The ability of UE2343 to access the CNS was assessed by
determining its concentration at plasma Cmax in the CSF.
Concentrations of UE2343 in the CSF ranged from 7.46 to
11.9% of total plasma levels and 25 to 40% of free plasma
levels, indicating moderate penetration of UE2343 into the
brain. The data were consistent with those obtained from pre-
clinical studies in rats where the UE2343 level in brain was
43% of the free plasma concentration.
The CSF data for UE2343 compare favourably with data
published for ABT-384, for which the CSF levels were 0.3 to
1% of total plasma levels (Katz et al., 2013). In this study,
the authors also measured deuterated cortisol adducts in the
CSF of two subjects in an effort to determine brain-specific in-
hibition of 11β-HSD1, and inferred complete inhibition of
brain enzyme at levels of ABT-384 in the CSF that were well
below its cellular IC50 and which would not be expected to
deliver significant 11β-HSD1 inhibition. We suspect the
changes in deuterated cortisol in CSF reflect inhibition of
11β-HSD1 by ABT-384 in liver and consequent changes in
plasma deuterated cortisol enrichment. In contrast, UE2343
would be expected to achieve concentrations in CSF up to
ninefold greater than its IC50 at Cmax and more than fivefold
its IC50 at Cmin following twice daily dosing of 35 mg. Trough
CSF, concentrations of UE2343 would also be expected to be
higher than its IC50 at doses of 10 and 20 mg b.i.d. Previous
preclinical studies have demonstrated that sub-maximal in-
hibition of 11β-HSD1 in the brain is sufficient to reverse
memory impairments in ageing and AD (Sooy et al., 2010;
Sooy et al., 2015). If translated to humans, it is likely that sim-
ilar levels of brain 11β-HSD1 inhibition will be sufficient to
provide cognitive enhancement. The failure of ABT-384 to
achieve an improvement in cognitive function in a Phase 2
study in AD patients may reflect inadequate inhibition of
brain 11β-HSD1 (Marek et al., 2014). The data described
herein suggest that the requisite level of 11β-HSD1 inhibition
in brain is achievable over a prolonged period following
twice-daily oral administration of UE2343.
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Figure S1 Adrenal steroid levels following single dose ad-
ministration. 6 healthy male and 2 healthy female subjects
per dose level. A. Cortisol, B. 4-androstenedione, C. testoster-
one and D. DHEA-s.
Figure S2 Adrenal steroid levels following multiple dose ad-
ministration. 8 healthy male subjects per dose level. A. Day 1
cortisol, B. Day 10 cortisol, C. 4-androstenedione, D. testos-
terone, E. DHEA-s.
Figure S3 ACTH levels following multiple dosing. 8 healthy
male subjects per dose level. A. Day 1 and B. Day 10.
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